Résumé
Background/Aims@#Chronic hepatitis C (CHC) patients who failed antiviral therapy are at increased risk for hepatocellular carcinoma (HCC). This study assessed the potential role of metformin and statins, medications for diabetes mellitus (DM) and hyperlipidemia (HLP), in reducing HCC risk among these patients. @*Methods@#We included CHC patients from the T-COACH study who failed antiviral therapy. We tracked the onset of HCC 1.5 years post-therapy by linking to Taiwan’s cancer registry data from 2003 to 2019. We accounted for death and liver transplantation as competing risks and employed Gray’s cumulative incidence and Cox subdistribution hazards models to analyze HCC development. @*Results@#Out of 2,779 patients, 480 (17.3%) developed HCC post-therapy. DM patients not using metformin had a 51% increased risk of HCC compared to non-DM patients, while HLP patients on statins had a 50% reduced risk compared to those without HLP. The 5-year HCC incidence was significantly higher for metformin non-users (16.5%) versus non-DM patients (11.3%; adjusted sub-distribution hazard ratio [aSHR]=1.51; P=0.007) and metformin users (3.1%; aSHR=1.59; P=0.022). Statin use in HLP patients correlated with a lower HCC risk (3.8%) compared to non-HLP patients (12.5%; aSHR=0.50; P<0.001). Notably, the increased HCC risk associated with non-use of metformin was primarily seen in non-cirrhotic patients, whereas statins decreased HCC risk in both cirrhotic and non-cirrhotic patients. @*Conclusions@#Metformin and statins may have a chemopreventive effect against HCC in CHC patients who failed antiviral therapy. These results support the need for personalized preventive strategies in managing HCC risk.
Résumé
Since the 13C-urea breath test [UBT] has become a highly reliable method for the noninvasive diagnosis of Helicobacter pylori infection, this study was performed in order to compare the sensitivity, specificity and accuracy among noninvasive tests including capsule UBT, conventional UBT and serology in the diagnosis of H. pylori infection. One hundred patients received capsule UBT, conventional UBT and gave blood samples for the diagnosis of H. pylori infection. Upper gastrointestinal endoscopy was performed in all patients. H. pylori infection was defined as the presence of a positive culture or positive results of both histology and rapid urease test [CLO test]. McNemar's test was used to determine the significance of differences among capsule UBT, conventional UBT and serology. Differences were considered significant at p < 0.05. According to the predefined criteria, the sensitivity, specificity, positive predictive value and negative predictive value of capsule UBT, conventional UBT and serology was 100, 95.7, 96.4 and 100%; 100, 85.1, 88.3 and 100%, and 90.6, 85.1, 82.7 and 88.9%, respectively. The accuracy of capsule UBT was higher than that of conventional UBT and serology [98 vs. 93 and 88%, respectively]. Capsule UBT had a similar ability for the detection of H. pylori infection compared with conventional UBT and serology [McNemar's test, p > 0.05]. According to our study, capsule UBT was highly accurate compared with other noninvasive tests including conventional UBT and serology. It could become a good alternative to endoscopy for the diagnosis of H. pylori infection